18α甘草酸二铵脂质复合物治疗慢性病毒性肝炎的疗效观察

Therapeutic efficacy of 18 α-Diammonium glycyrrhizinate phosphatidylcholine complex in patients with chronic virus hepatitis

目的探讨18α甘草酸二铵脂质复合物与甘草酸二铵胶囊治疗慢性病毒性肝炎的疗效和安全性。方法慢性乙型或丙型病毒性肝炎患者55例，随机分为治疗组和对照组。治疗组给予18α甘草酸二铵脂质复合物（50mg／粒）治疗，对照组给予甘草酸二铵胶囊（50mg／粒）治疗；治疗剂量相同：第1～10周每次3粒，第11周每次2粒，第12周每次1粒；每日3次；停药后均随访4周。观察治疗过程中肝功能的动态变化及治疗12周时丙氨酸氨基转移酶（ALT）复常率和随访结束时的复发率。结果两组患者治疗前资料可比性良好。治疗组患者治疗4、8、12周时ALT与治疗前相比明显下降（P=0.00）；而对照组仅在治疗至12周时才有明显下降（P〈0．05）。治疗结束时治疗组和对照组的ALT复常率分别为38．5％和34．5％（P=0．76）。组间不良反应发生率相似。结论18α甘草酸二铵脂质复合物可快速、安全地降低慢性乙、丙型病毒性肝类患者的囊．表转夥酶．

Objective To investigate the therapeutic efficacy and safety of 18 α-Diammonium glycyrrhizinate phosphatidylcholine complex （ DGPC ） in patients with chronic hepatitis B and or C with elevated aminotransferase. Methods 55 patients with chronic hepatitis B and or C,with serum alanine aminotransferase （ ALT） of 2 to 10 times the upper limit of normal were randomly assigned to receive DGPC or Diammonium glycyrrhizinate （ DG） for 12 weeks. Then they were followed up for an additional 4 weeks. From week 1 to 10, DGPC or DG was given as 150 mg,three times a day （TID）. At the lhh week,the drug was given as 100 mg,TID. Then 50 mg,TID for the 12th week. Results ALT was markedly decreased after receiving DGPC 4,8,12 weeks （ P = 0.00 ）. ALT normali- zation rate at the end of therapy was similar （ 38.5% vs 34.5% ,P = 0.76 ）. Drug-related adverse events were similar. Conclusion DGPC can rapidly and safely decrease aminotransferase in patients with chronic viurs hepatitis.